NASDAQ:ORPN Bioblast Pharma (ORPN) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.60▼$2.6350-Day Range$11.50▼$28.4952-Week Range$6.16▼$30.00Volume26,876 shsAverage VolumeN/AMarket Capitalization$1.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media About Bioblast Pharma (NASDAQ:ORPN) StockEnlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.Read More Receive ORPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ORPN Stock News HeadlinesMarch 31, 2023 | wsj.comChangzhou Qianhong Bio-Pharma Co. Ltd. AMarch 1, 2023 | marketwatch.com2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for DevelopmentJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.February 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028February 15, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028February 13, 2023 | thestreet.comBioBlast Scant Data Links Drug to Improved Swallowing in PatientsJanuary 30, 2023 | seekingalpha.comBioMarin: Opportunity To Score Home Run With Latest Regulatory AdvancementsJanuary 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028June 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.October 16, 2022 | finance.yahoo.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027September 21, 2022 | seekingalpha.comENLV Enlivex Therapeutics Ltd.August 31, 2022 | marketwatch.comBioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans ProgressivaAugust 31, 2022 | msn.comBioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease CandidateAugust 12, 2022 | finance.yahoo.comAro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe DiseaseAugust 11, 2022 | seekingalpha.comBioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call TranscriptAugust 1, 2022 | finance.yahoo.comBiosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic SyndromesJuly 12, 2022 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell LymphomaJuly 8, 2022 | apnews.comGlobal Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.comJuly 7, 2022 | apnews.comPyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDAJune 30, 2022 | marketwatch.comAura Biosciences Gets Fast Track Designation for AU-011 Bladder Cancer TreatmentJune 7, 2022 | markets.businessinsider.comProlacta Bioscience Appoints David Steinberg as Chief Financial OfficerMay 25, 2022 | apnews.comENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic CancerMay 12, 2022 | finance.yahoo.comStealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular DystrophySeptember 17, 2021 | prnewswire.comGlobal Genetic Disorders Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021September 10, 2020 | marketwatch.comSpinal Muscular Atrophy Medicine Market Share Analysis, Trends, Segmentation, Top Players Analysis, Growth and COVID-19 Impact Forecast by 2020-2026March 6, 2019 | finance.yahoo.comBioblast Announces Effectiveness of Eight to One Reverse SplitFebruary 19, 2019 | seekingalpha.comBioBlast up 64% on Trehalose deal with SeelosSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORPN CUSIPN/A CIK1596812 Webbioblastpharma.com Phone(722) 670-8072FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.56 per share Price / Book0.35Miscellaneous Outstanding Shares420,000Free FloatN/AMarket Cap$1.10 million OptionableNot Optionable Beta1.41 Key ExecutivesOren HershkovitzChief Executive OfficerShachar ShlosbergerChief Financial OfficerDror MevorachChief Scientific & Medical OfficerOdelia Ben-ShitritHead-Clinical OperationsKey CompetitorsAltamira TherapeuticsNASDAQ:CYTOScopus BioPharmaNASDAQ:SCPSPLx PharmaNASDAQ:PLXPTricidaNASDAQ:TCDAQBiodexa PharmaceuticalsNASDAQ:BDRXView All Competitors ORPN Stock - Frequently Asked Questions When did Bioblast Pharma's stock split? Shares of Bioblast Pharma reverse split on the morning of Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Bioblast Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO). What is Bioblast Pharma's stock symbol? Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN." What is Bioblast Pharma's stock price today? One share of ORPN stock can currently be purchased for approximately $2.62. How much money does Bioblast Pharma make? Bioblast Pharma (NASDAQ:ORPN) has a market capitalization of $1.10 million. How can I contact Bioblast Pharma? Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The official website for the company is bioblastpharma.com. The biopharmaceutical company can be reached via phone at (722) 670-8072 or via email at ir@bioblastpharma.com. This page (NASDAQ:ORPN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.